Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Davis

Physician Assistant, Medical Lake Oswego, OR Physician Assistant

NPI 1508928714 CMS profile 10446055

123 C Ave, Lake Oswego, OR 97034

Open in the dashboard

General payments

$12,288

612 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Davis of Lake Oswego, OR is reported in the CMS Open Payments database as having received $12,288 across 612 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,700 156
2024 General $3,232 148
2023 General $3,800 180
2022 General $1,940 92
2021 General $615 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Davis
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mark Davis were reported at $2,700. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mark Davis Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $615 $156 $41–$563 $132
2022 $1,940 $185 $55–$649 $149
2023 $3,800 $199 $58–$717 $160
2024 $3,232 $206 $62–$740 $164
2025 $2,700 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,999 150 payments
  2. AbbVie, Inc. $2,089 111 payments
  3. Novartis Pharmaceuticals Corporation $1,369 88 payments
  4. E.R. Squibb & Sons, L.L.C. $1,050 44 payments
  5. Lilly USA, LLC $926 45 payments
  6. Pfizer Inc. $622 34 payments
  7. Arcutis Biotherapeutics, Inc. $541 27 payments
  8. Regeneron Healthcare Solutions, Inc. $466 14 payments
  9. UCB, Inc. $377 20 payments
  10. Amgen Inc. $369 20 payments
  11. Other $1,478 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,453 600 payments
  2. Education $835 12 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,263 105 payments
  2. SIMPONI ARIA $1,227 73 payments
  3. STELARA $1,227 73 payments
  4. SIMPONI $1,227 73 payments
  5. SKYRIZI $1,220 69 payments
  6. SOTYKTU $1,050 44 payments
  7. COSENTYX $899 69 payments
  8. REMICADE $736 45 payments
  9. RINVOQ $521 23 payments
  10. CIBINQO $505 28 payments
  11. Other $5,705 286 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

773

Median for Physician Assistant: 241

Drug cost

$73,197

Median for Physician Assistant: $4,110

Branded share of claims

3.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 15 $55,428
Tacrolimus Generic 29 $3,827
Ketoconazole Generic 178 $2,906
Clobetasol Propionate Generic 63 $1,876
Triamcinolone Acetonide Generic 137 $1,681
Tretinoin Generic 20 $1,416
Ciclopirox Generic 35 $1,249
Doxycycline Monohydrate Generic 37 $831
Minoxidil Generic 71 $778
Betamethasone Valerate Generic 15 $554

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$79,772

Of which drugs: $15,523

Medicare patients

186

Average age 72

Services billed

1,493

91 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Arthritis 35%
Ischemic heart disease 19%
Diabetes 18%
Atrial fibrillation 17%
Depression 17%
Chronic kidney disease 16%
Heart failure 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 17 50 $15,518

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$611 — —
SOTYKTU
$490 — —
COSENTYX
$308 — —
SKYRIZI
$279 — —
VTAMA
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

612 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record